Medical Imaging Agents Global Market – Forecast to 2026

Publishing Date : October, 2019
Report Code : HCPH0114
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Chemical substances that improve the visibility of specific organs, tissues or blood vessel during a diagnostic imaging investigation are known as medical imaging agents which comprises of contrast agents and nuclear medicine. These substances are administered directly through veins, arteries, and joints or consumed orally. X-ray and computed tomography (CT) imaging exams makes use of iodinated and barium based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of body are working and any associated abnormalities.  Ultrasound scans makes use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhances the details of heart, liver and kidney. Nuclear medicine is a highly multi-disciplined medical imaging specialty sector that uses small amounts of radioactive material in order to diagnose diseases. According to IQ4I estimates, the Medical imaging agents market is expected to grow at mid single digit CAGR of from 2019 to 2026 to reach $12,290.7 million by 2026.

Medical imaging agents global market by molecule/isotope segmented into contrast agents and nuclear medicine. According IQ4I Research, the contrast agents global market is expected to grow at a mid single digit CAGR from 2019 to 2026. The contrast agents global market by molecule is segmented into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium, iron and dyes. Iodine-based contrast agents market held the largest market revenue in 2019 and microbubble segment is the fastest growing segment at double digit CAGR from 2019 to 2026 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agents market accounted the largest share in 2019. Non-ionic iodine contrast agents are used more because of lower osmolality, they are better tolerated and another advantage is that, they appear to have less toxicity. Ionic Iodine based contrasts are further segmented by its chemical structure into monomers and dimers. Monomers market accounted for the largest share in 2019. Non-Ionic Iodine based contrasts are further segmented by its chemical structure into monomeric and dimeric. Monomerics market accounted the largest share in 2019 and is projected to grow at a low single digit CAGR from 2019 to 2026 as they are safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity.

As estimated by IQ4I Research, the nuclear medicine global market is poised to grow at a mid single digit CAGR from 2019 to 2026. Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipments are the opportunities likely to propel the growth of nuclear medicine market.

The nuclear medicine global market by isotopes are segmented into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Xe-133, Samarium (Sm-153), Rhenium (Re-186), Flurodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Technetium (Tc-99m) isotope market held largest revenue in 2019 and expected to grow at mid single digit CAGR from 2019 to 2026 and Flurodeoxyglucose (18F-FDG) is projected to grow at a strong CAGR from 2019 to 2026 due to accuracy.

The Medical imaging agents market by modality is segmented into X-Ray/CT, MRI, Ultrasound, SPECT and PET. X-Ray/CT market held the largest market revenue in 2019 and ultrasound segment is growing rapidly at high double digit CAGR from 2019 to 2026 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.

The Medical imaging agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, pulmonary, hepatology and others which include neck, bone and salivary gland imaging. Cardiovascular market accounted for the largest share in 2019 and cancer is the fastest growing market with projected single digit CAGR growth from 2019 to 2026 due to increase in cancer imaging such as lung, thyroid and breast cancer imaging procedures using Iodine, Gadolinium and microbubble contrast agents and radiopharmaceuticals. Medical imaging agents market by route of administration is segmented into intravascular, oral, rectal and others, which include intraosseous, intrathecal and intravesicle. Intravascular accounted for largest share in 2019 and is the fastest growing market with projected mid single digit CAGR from 2019 to 2026 due to increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium, microbubble contrast agent and nuclear medicine to be administered intravascular.

Medical imaging agents market by imaging is segmented into diagnostic and interventional imaging. Diagnostic imaging commanded the largest revenue in 2019 and expected to grow at a CAGR low single digit CAGR from 2019 to 2026. Interventional imaging segment is estimated to grow rapidly at double digit CAGR from 2019 to 2026 due to increase in image guide procedures and increase in aging population who usually opt minimally invasive procedures.

Medical imaging based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. Hospitals market accounted largest share in 2019, the rising demand for the diagnosis using CT or X-Ray, MRI, ultrasound, SPECT and PET imaging procedures due to increase in incidence and prevalence of diseases, ready availability of cyclotrons for generation of isotopes and presence of trained technicians who can handle radioisotopes. Diagnostic & Ambulatory surgical centers is the fastest growing market and is estimated to grow at mid single digit CAGR from 2019 to 2026 due to increase in number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).

Geographically, North America region commanded the largest revenue in 2019 due to favorable reimbursement coverage, technological advancement in equipment, increased utilization of fusion imaging and increase in incidence and prevalence of diseases conditions due to change in lifestyle, obesity has led the market growth in this region. However, Asia-Pacific region is the fastest growing market and is expected to grow at double digit CAGR from 2019 to 2026 due to increased healthcare awareness, improved economic growth, large patient pool, and rising aged population.

The Medical imaging agents global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players in the Medical imaging agents global market are Bayer Group (Germany), Bracco Group (Italy), Curium Pharma (France), Cardinal Health (U.S),  Fujifilm Holding Corporation (Japan), Fujipharma Co. Ltd (Japan), GE Company (GE Healthcare) (U.S.), Guerbet (France), Jubilant Life science (India), Lantheus Medical Imaging (U.S.) and Novartis International AG (Advanced accelerator) (Switzerland).

 

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World (RoW)

     

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT SCOPE
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING DEMAND FOR IMAGING AGENT-ASSISTED DIAGNOSTIC PROCEDURES
        • 3.3.1.2     PRODUCTION OF RADIOPHARMACEUTICALS FROM CYCLOTRONS
        • 3.3.1.3     THE GROWTH OF MEDICAL IMAGING TECHNOLOGIES IN EMERGING MARKETS
        • 3.3.1.4     USAGE OF HYBRID IMAGING
        • 3.3.1.5     FAVORABLE REIMBURSEMENT
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SIDE EFFECT ASSOCIATED WITH MEDICAL IMAGING AGENTS
        • 3.3.2.2     THE SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS
        • 3.3.2.3     SHORTAGE OF RADIOLOGIST AND QUALIFIED TECHNICIANS
        • 3.3.2.4     HIGH COST AND SUPPLY SHORTAGE OF ISOTOPES
        • 3.3.2.5     STRINGENT REGULATIONS FOR MANUFACTURING AND MARKETING OF MEDICAL IMAGING AGENTS
    • 3.4     REGULATORY GUIDELINES
      • 3.4.1     UNITED STATES
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     JAPAN
      • 3.4.5     INDIA
      • 3.4.6     SOUTH KOREA
    • 3.5     REIMBURSEMENT TABLE
    • 3.6     UPCOMING TECHNOLOGY
      • 3.6.1     NEAR-INFRARED FLUORESCENT IMAGING
      • 3.6.2     TARGETED CONTRAST AGENT
    • 3.7     CLINICAL TRIALS
      • 3.7.1     CONTRAST AGENTS CLINICAL TRIAL
        • 3.7.1.1     GADOLINIUM BASED CONTRAST AGENTS
        • 3.7.1.2     IODINATED CONTRAST AGENTS
        • 3.7.1.3     IRON OXIDE CONTRAST AGENTS
        • 3.7.1.4     MANGANESE BASED CONTRAST AGENTS
      • 3.7.2     NUCLEAR MEDICINE CLINICAL TRIALS
        • 3.7.2.1     PET BASED IMAGING AGENTS (FDG)
        • 3.7.2.2     F-18 BASED AGENTS
        • 3.7.2.3     XE-133 BASED AGENTS
        • 3.7.2.4     GA-68 BASED AGENTS
    • 3.8     SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE
      • 3.8.1     REACTORS
      • 3.8.2     PROCESSING FACILITY
      • 3.8.3     GENERATORS MANUFACTURING UNITS
      • 3.8.4     HOSPITALS AND CENTRAL RADIO PHARMACIES
    • 3.9     LIST OF CURRENT IRRADIATORS AND PROCESSORS OF TECHNITUM 99
    • 3.10     SUPPLY CHAIN ANALYSIS OF CONTRAST AGENTS
    • 3.11     PATENT TRENDS
    • 3.12     PORTER’S FIVE FORCE ANALYSIS
      • 3.12.1     THREAT OF NEW ENTRANTS
      • 3.12.2     THREAT OF SUBSTITUTES
      • 3.12.3     BARGAINING POWER OF SUPPLIERS
      • 3.12.4     BARGAINING POWER OF BUYERS
      • 3.12.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.13     MARKET SHARE ANALYSIS
      • 3.13.1     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.13.2     MARKET SHARE ANALYSIS OF CONTRAST AGENTS
      • 3.13.3     MARKET SHARE ANALYSIS OF NUCLEAR MEDICINE
      • 3.13.4     MARKET SHARE ANALYSIS OF MRI
      • 3.13.5     MARKET SHARE ANALYSIS OF X-RAY/CT
      • 3.13.6     MARKET SHARE ANALYSIS OF ULTRASOUND AGENTS
      • 3.13.7     MARKET SHARE ANALYSIS OF SPECT AGENTS
      • 3.13.8     MARKET SHARE ANALYSIS OF PET AGENTS
    • 3.14     MEDICAL IMAGING AGENTS GLOBAL CONSUMPTION DATA
      • 3.14.1     X-RAY/CT GLOBAL COMSUMPTION VOLUME
      • 3.14.2     MRI GLOBAL COMSUMPTION VOLUME
      • 3.14.3     ULTRASOUND GLOBAL COMSUMPTION VOLUME
    • 3.15     MEDICAL IMAGING PROCEDURAL VOLUME
      • 3.15.1     X-RAY/CTCONTRAST AGENTS GLOBAL PROCEDURAL VOLUME
      • 3.15.2     MRI CONTRAST AGENTS GLOBAL PROCEDURAL VOLUME
      • 3.15.3     ULTRASOUND CONTRAST AGENTS GLOBAL PROCEDURAL VOLUME
  • 4     MEDICAL IMAGING AGENTS GLOBAL MARKET, BY MOLECULE/ISOTOPE
    • 4.1     INTRODUCTION
    • 4.2     CONTRAST AGENTS
      • 4.2.1     IODINATED CONTRAST AGENTS
        • 4.2.1.1     IODINATED IONIC CONTRAST AGENTS
          • 4.2.1.1.1     MONOMERS
          • 4.2.1.1.2     DIMER
        • 4.2.1.2     IODINATED NON-IONIC CONTRAST AGENTS
          • 4.2.1.2.1     MONOMER
          • 4.2.1.2.2     DIMER
      • 4.2.2     GADOLINIUM-BASED CONTRAST AGENTS
        • 4.2.2.1     MACROCYCLIC CONTRAST AGENTS
          • 4.2.2.1.1     IONIC MACROCYCLIC CONTRAST AGENTS
          • 4.2.2.1.2     NON-IONIC MACROCYCLIC CONTRAST AGENTS
        • 4.2.2.2     LINEAR GADOLINIUM BASED CONTRAST AGENTS
          • 4.2.2.2.1     IONIC LINEAR CONTRAST AGENTS
          • 4.2.2.2.2     NON-IONIC LINEAR CONTRAST AGENTS
      • 4.2.3     MICROBUBBLE BASED CONTRAST AGENTS
      • 4.2.4     OTHERS CONTRAST AGENTS
    • 4.3     NUCLEAR MEDICINE
      • 4.3.1     TECHNETIUM (TC-99M)
      • 4.3.2     THALLIUM (TL-201)
      • 4.3.3     GALLIUM (GA-67)
      • 4.3.4     IODINE (I-123)
      • 4.3.5     XENON (XE-133)
      • 4.3.6     SAMARIUM (SM-153)
      • 4.3.7     RHENIUM (RE-186)
      • 4.3.8     FLUORODEOXYGLUCOSE (18F-FDG)
      • 4.3.9     GALLIUM (GA-68)
      • 4.3.10     RUBIDIUM (RB-82)
      • 4.3.11     OTHERS
  • 5     MEDICAL IMAGING AGENTS GLOBAL MARKET, BY MODALITY
    • 5.1     INTRODUCTION
    • 5.2     X-RAY/COMPUTED TOMOGRAPHY (CT)
    • 5.3     MAGNETIC RESONANCE IMAGING (MRI)
    • 5.4     ULTRASOUND
    • 5.5     SINGLE PHOTO EMISSION COMPUTED TOMOGRAPHY (SPECT)
    • 5.6     POSITRON EMISSION TOMOGRAPHY(PET)
  • 6     MEDICAL IMAGING AGENTS GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     CARDIOVASCULAR
    • 6.3     CANCER
    • 6.4     GASTROINTESTINAL
    • 6.5     MUSCULOSKELETAL
    • 6.6     NEUROLOGY
    • 6.7     NEPHROLOGY
    • 6.8     OBSTETRICS AND GYNECOLOGY
    • 6.9     PULMONARY
    • 6.10     HEPATOLOGY
    • 6.11     OTHERS
  • 7     MEDICAL IMAGING AGENTS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION
    • 7.1     INTRODUCTION
    • 7.2     INTRAVASCULAR
    • 7.3     ORAL
    • 7.4     RECTAL
    • 7.5     OTHERS
  • 8     MEDICAL IMAGING AGENTS GLOBAL MARKET, BY IMAGING
    • 8.1     INTRODUCTION
    • 8.2     DIAGNOSTIC IMAGING
    • 8.3     INTERVENTIONAL IMAGING
  • 9     MEDICAL IMAGING AGENTS GLOBAL MARKET, BY END-USERS
    • 9.1     INTRODUCTION
    • 9.2     HOSPITAL
    • 9.3     DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
    • 9.4     OTHER END-USER
  • 10     REGIONAL ANALYSIS
    • 10.1     INTRODUCTION
    • 10.2     NORTH AMERICA
      • 10.2.1     U.S.
      • 10.2.2     REST OF N.A.
    • 10.3     EUROPE
      • 10.3.1     GERMANY
      • 10.3.2     FRANCE
      • 10.3.3     U.K.
      • 10.3.4     REST OF EUROPE
    • 10.4     ASIA-PACIFIC
      • 10.4.1     CHINA
      • 10.4.2     JAPAN
      • 10.4.3     SOUTH KOREA
      • 10.4.4     REST OF ASIA-PACIFIC
    • 10.5     REST OF THE WORLD
      • 10.5.1     TURKEY
      • 10.5.2     BRAZIL
      • 10.5.3     OTHERS
  • 11     COMPETITIVE LANDSCAPE
    • 11.1     INTRODUCTION
    • 11.2     COLLABORATIONS, AGREEMENTS AND PARTNERSHIP
    • 11.3     APPROVALS
    • 11.4     OTHER KEY DEVELOPMENT
  • 12     MAJOR PLAYER PROFILES
    • 12.1     BAYER GROUP
      • 12.1.1     OVERVIEW
      • 12.1.2     FINANCIALS
      • 12.1.3     PRODUCT PORTFOLIO
      • 12.1.4     KEY DEVELOPMENTS
      • 12.1.5     BUSINESS STRATEGY
      • 12.1.6     SWOT ANALYSIS
    • 12.2     BRACCO GROUP
      • 12.2.1     OVERVIEW
      • 12.2.2     FINANCIALS
      • 12.2.3     PRODUCT PORTFOLIO
      • 12.2.4     KEY DEVELOPMENTS
      • 12.2.5     BUSINESS STRATEGY
      • 12.2.6     SWOT ANALYSIS
    • 12.3     CARDINAL HEALTH INC.
      • 12.3.1     OVERVIEW
      • 12.3.2     FINANCIALS
      • 12.3.3     PRODUCT PORTFOLIO
      • 12.3.4     KEY DEVELOPMENTS
      • 12.3.5     BUSINESS STRATEGY
      • 12.3.6     SWOT ANALYSIS
    • 12.4     CURIUM PHARMA
      • 12.4.1     OVERVIEW
      • 12.4.2     FINANCIALS
      • 12.4.3     PRODUCT PORTFOLIO
      • 12.4.4     KEY DEVELOPMENTS
      • 12.4.5     BUSINESS STRATEGY
      • 12.4.6     SWOT ANALYSIS
    • 12.5     FUJIFILM HOLDINGS CORPORATION
      • 12.5.1     OVERVIEW
      • 12.5.2     FINANCIALS
      • 12.5.3     PRODUCT PORTFOLIO
      • 12.5.4     KEY DEVELOPMENTS
      • 12.5.5     BUSINESS STRATEGY
      • 12.5.6     SWOT ANALYSIS
    • 12.6     FUJIPHARMA CO LTD
      • 12.6.1     OVERVIEW
      • 12.6.2     FINANCIALS
      • 12.6.3     PRODUCT PORTFOLIO
      • 12.6.4     KEY DEVELOPMENTS
      • 12.6.5     BUSINESS STRATEGY
      • 12.6.6     SWOT ANALYSIS
    • 12.7     GE COMPANY (GE HEALTHCARE)
      • 12.7.1     OVERVIEW
      • 12.7.2     FINANCIALS
      • 12.7.3     PRODUCT PORTFOLIO
      • 12.7.5     BUSINESS STRATEGY
      • 12.7.6     SWOT ANALYSIS
    • 12.8     GUERBET
      • 12.8.1     OVERVIEW
      • 12.8.2     FINANCIALS
      • 12.8.3     PRODUCT PORTFOLIO
      • 12.8.4     KEY DEVELOPMENTS
      • 12.8.5     BUSINESS STRATEGY
      • 12.8.6     SWOT ANALYSIS
    • 12.9     JUBILANT LIFESCIENCES
      • 12.9.1     OVERVIEW
      • 12.9.2     FINANCIALS
      • 12.9.3     PRODUCT PORTFOLIO
      • 12.9.4     KEY DEVELOPMENTS
      • 12.9.5     BUSINESS SRATEGY
      • 12.9.6     SWOT ANALYSIS
    • 12.10     LANTHEUS MEDICAL IMAGING INC.
      • 12.10.1     OVERVIEW
      • 12.10.2     FINANCIALS
      • 12.10.3     PRODUCT PORTFOLIO
      • 12.10.4     KEY DEVELOPMENTS
      • 12.10.5     BUSINESS STRATEGY
      • 12.10.6     SWOT ANALYSIS
    • 12.11     NOVARTIS (ADVANCE ACCELERATOR APPLICATIONS S.A.)
      • 12.11.1     OVERVIEW
      • 12.11.2     FINANCIALS
      • 12.11.3     PRODUCT PORTFOLIO
      • 12.11.4     KEY DEVELOPMENTS
      • 12.11.5     BUSINESS STRATEGY
      • 12.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 2     TECHNETIUM (TC-99M) REACTORS
      • TABLE 3     CURRENT IRRADIATORS INCLUDING THOSE IN TRANSITION BY 2023
      • TABLE 4     CURRENT PROCESSORS INCLUDING THOSE IN TRANSITION BY 2023
      • TABLE 5     POTENTIAL IRRADIATIONS ENTERING IN PERIOD 2018 TO 2023
      • TABLE 6     POTENTIAL PROCESSORS ENTERING IN PERIOD 2018 TO 2023
      • TABLE 7     X-RAY/CT CONTRAST AGENTS GLOBAL CONSUMPTION, BY REGION, (2018-2026) (L)
      • TABLE 8     MRI CONTRAST AGENTS GLOBAL CONSUMPTION, BY REGION, (2018-2026) (L)
      • TABLE 9     ULTRASOUND IMAGING AGENTS GLOBAL CONSUMPTION, BY REGION, (2018-2026) (L)
      • TABLE 10     X-RAY/CT CONTRAST AGENTS GLOBAL PROCEDURAL VOLUME, BY REGION, (2018-2026) (NO’S)
      • TABLE 11     MRI CONTRAST AGENTS GLOBAL PROCEDURAL VOLUME, BY REGION, (2018-2026) (NO’S)
      • TABLE 12     ULTRASOUND CONTRAST AGENTS GLOBAL PROCEDURAL VOLUME, BY REGION, (2018-2026) (NO’S)
      • TABLE 13     SPECT GLOBAL PROCEDURAL VOLUME, BY REGION, (2018-2026) (NO’S)
      • TABLE 14     PET GLOBAL PROCEDURAL VOLUME, BY REGION, (2018-2026) (NO)
      • TABLE 15     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 16     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY MOLECULE/ISOTOPE, (2018-2026) ($MN)
      • TABLE 17     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 18     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY MOLECULE, (2018-2026) ($MN)
      • TABLE 19     IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 20     IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 21     IODINATED IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 22     IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 23     MONOMER IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 24     IODINATED NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 25     NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 26     MONOMER NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 27     DIMER NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 28     GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 29     GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 30     MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 31     MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 32     IONIC MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 33     NON-IONIC MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 34     LINEAR GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 35     LINEAR GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 36     IONIC LINEAR CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 37     NON-IONIC LINEAR CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 38     MICROBUBBLE BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 39     OTHER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 40     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 41     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY ISOTOPE, (2018-2026) ($MN)
      • TABLE 42     TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 43     THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 44     GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 45     IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 46     XENON (XE-133) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 47     SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 48     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 49     FLURODEOXYGLUCOSE(18F-FDG) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 50     GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 51     RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 52     OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 53     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY MODALITY, (2018-2026) ($MN)
      • TABLE 54     X-RAY/CT GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 55     MRI GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 56     ULTRASOUND GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 57     SPECT GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 58     PET GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 59     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 60     CARDIOVASCULAR GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 61     CANCER GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 62     GASTROINTESTINAL GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 63     MUSCULOSKELETAL GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 64     NEUROLOGY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 65     NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 66     OBSTETRICS AND GYNECOLOGY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 67     PULMONARY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 68     HEPATOLOGY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 69     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 70     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2018-2026) ($MN)
      • TABLE 71     INTRAVASCULAR GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 72     ORAL GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 73     RECTAL GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 74     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 75     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY IMAGING, (2018-2026) ($MN)
      • TABLE 76     DIAGNOSTIC IMAGING GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 77     INTERVENTIONAL IMAGING GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 78     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 79     HOSPITAL GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 80     DIAGNOSTIC & AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 81     OTHER END-USER GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 82     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
      • TABLE 83     NORTH AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE, (2018-2026) ($MN)
      • TABLE 84     NORTH-AMERICA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2018-2026) ($MN)
      • TABLE 85     NORTH-AMERICA IODINATED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 86     NORTH-AMERICA IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE (2018-2026) ($MN)
      • TABLE 87     NORTH-AMERICA NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 88     NORTH-AMERICA GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 89     NORTH-AMERICA MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 90     NORTH-AMERICA LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 91     NORTH-AMERICA NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE, (2018-2026) ($MN)
      • TABLE 92     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY, (2018-2026) ($MN)
      • TABLE 93     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 94     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2018-2026) ($MN)
      • TABLE 95     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING, (2018-2026) ($MN)
      • TABLE 96     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 97     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 98     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE, (2018-2026) ($MN)
      • TABLE 99     EUROPE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2018-2026) ($MN)
      • TABLE 100     EUROPE IODINATED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 101     EUROPE IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 102     EUROPE NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 103     EUROPE GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 104     EUROPE MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 105     EUROPE LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 106     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE, (2018-2026) ($MN)
      • TABLE 107     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY, (2018-2026) ($MN)
      • TABLE 108     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 109     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2018-2026) ($MN)
      • TABLE 110     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2018-2026) ($MN)
      • TABLE 111     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 112     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 113     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE, (2018-2026) ($MN)
      • TABLE 114     APAC CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2018-2026) ($MN)
      • TABLE 115     APAC IODINATED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 116     APAC IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 117     APAC NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 118     APAC GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 119     APAC MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 120     APAC LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 121     APAC NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE, (2018-2026) ($MN)
      • TABLE 122     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY, (2018-2026) ($MN)
      • TABLE 123     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 124     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2018-2026) ($MN)
      • TABLE 125     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2018-2026) ($MN)
      • TABLE 126     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 127     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 128     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE, (2018-2026) ($MN)
      • TABLE 129     ROW CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2018-2026) ($MN)
      • TABLE 130     ROW IODINATED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 131     ROW IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 132     ROW NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 133     ROW GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2018-2026) ($MN)
      • TABLE 134     ROW MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 135     ROW LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018-2026) ($MN)
      • TABLE 136     ROW NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE, (2018-2026) ($MN)
      • TABLE 137     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY, (2018-2026) ($MN)
      • TABLE 138     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
      • TABLE 139     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2018-2026) ($MN)
      • TABLE 140     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2018-2026) ($MN)
      • TABLE 141     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER, (2018-2026) ($MN)
      • TABLE 142     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
      • TABLE 143     COLLABORATION, AGREEMENT & PARTNERSHIPS (2018-2019)
      • TABLE 144     APPROVALS (2018-2019)
      • TABLE 145     BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2017-2019) (Q2) ($MN)
      • TABLE 146     BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2017-2019) (Q2) ($MN)
      • TABLE 147     BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) (Q2) ($MN)
      • TABLE 148     CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
      • TABLE 149     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN)
      • TABLE 150     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 151     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2016 – 2018) ($MN)
      • TABLE 152     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 153     FUJIFILM HOLDING CORPORATION: HEALTHCARE & MATERIALS REVENUE, BY SUB-SEGMENTS (2016-2018) ($MN)
      • TABLE 154     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2016 – 2018) ($MN)
      • TABLE 155     FUJIPHARMA CO LTD: TOTAL REVENUE AND R&D EXPENSES, (2017–2019) (Q3) ($MN)
      • TABLE 156     FUJIPHARMA CO LTD: TOTAL REVENUE, BY SEGMENTS (2017-2019) (Q3) ($MN)
      • TABLE 157     FUJIPHARMA CO LTD: TOTAL REVENUE, BY SUB-SEGMENTS (2017-2019) (Q3) ($MN)
      • TABLE 158     GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2017 – 2019) (Q2) ($MN)
      • TABLE 159     GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2017-2019) (Q2) ($MN)
      • TABLE 160     GE COMPANY: TOTAL REVENUE, BY HEALTHCARE SEGMENT (2017 –2019) (Q2) ($MN)
      • TABLE 161     GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2017 –2019) (Q2) ($MN)
      • TABLE 162     GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q2) ($MN)
      • TABLE 163     GUERBET: SEGMENTAL REVENUE (2017-2019) (Q2) ($MN)
      • TABLE 164     GUERBET: SUB-SEGMENTAL REVENUE (2017-2019) (Q2) ($MN)
      • TABLE 165     GUERBET: GEOGRAPHIC REVENUE (2017-2019) (Q2) ($MN)
      • TABLE 166     JUBILANT LIFESCIENCE: TOTAL REVENUE AND R&D EXPENSES (2016–2018) ($MN)
      • TABLE 167     JUBILANT LIFESCIENCE: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 168     JUBILANT LIFESCIENCE: PHARMACEUTICAL TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 169     JUBILANT LIFESCIENCE: SPCEIALTY PHARMACEUTICAL INJECTABLES TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 170     JUBILANT LIFESCIENCE: TOTAL REVENUE, BY GEOGRAPHY (2016 – 2018) ($MN)
      • TABLE 171     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q2) ($MN)
      • TABLE 172     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2017-2019) (Q2) ($MN)
      • TABLE 173     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
      • TABLE 174     NOVARTIS(AAA): TOTAL REVENUE AND R&D EXPENSES (2017-2019) (Q2) ($MN)
      • TABLE 175     NOVARTIS (AAA): TOTAL REVENUE, BY SEGMENTS (2017-2019) (Q2) ($MN)
      • TABLE 176     NOVARTIS (AAA): TOTAL REVENUE, BY GEOGRAPHY (2017-2019) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: MEDICAL IMAGING AGENTS GLOBAL MARKET
      • FIGURE 3     MEDICAL IMAGING AGENTS GLOBALMARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     MEDICAL IMAGING AGENTS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     MEDICAL IMAGING AGENTS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     MEDICAL IMAGING AGENTS GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     TECHNETIUM -99: SUPPLY CHAIN ANALYSIS
      • FIGURE 9     CONTRAST AGENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     MEDICINE IMAGING GLOBAL MARKET: PCT PATENT FILING BY MAJOR PLAYERS (2015-2019)
      • FIGURE 11     MEDICAL IMAGING AGENTS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 12     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 13     CONTRAST AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 14     NUCLEAR MEDICINE GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 15     MRI GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 16     X-RAY/CT AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 17     ULTRASOUND AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 18     SPECT AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 19     PET AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
      • FIGURE 20     REGIONAL AND COUNTRYWISE CONSUMPTION OF X-RAY/CT CONTRAST AGENTS IN LITERS: (2019)(L)
      • FIGURE 21     COUNTRYWISE CONSUMPTION OF X-RAY/CT CONTRAST AGENTS IN LITERS: (2019)(L)
      • FIGURE 22     REGIONAL AND COUNTRYWISE CONSUMPTION OF MRI CONTRAST AGENTS IN LITERS: (2019)(L)
      • FIGURE 23     COUNTRYWISE CONSUMPTION OF MRI CONTRAST AGENTS IN LITERS: (2019)(L)
      • FIGURE 24     REGIONAL AND COUNTRYWISE CONSUMPTION OF ULTRASOUND CONTRAST AGENTS IN LITERS: (2019)(L)
      • FIGURE 25     COUNTRYWISE CONSUMPTION OF ULTRASOUND CONTRAST AGENTS IN LITERS: (2019)(L)
      • FIGURE 26     REGIONAL AND COUNTRYWISE X-RAY/CT CONTRAST AGENTS PROCEDURAL VOLUME: (2019)(NO’S)
      • FIGURE 27     REGIONAL AND COUNTRYWISE MRI CONTRAST AGENTS PROCEDURAL VOLUME: (2019)(NO’S)
      • FIGURE 28     REGIONAL AND COUNTRYWISE ULTRASOUND CONTRAST AGENTS PROCEDURAL VOLUME: (2019)(NO’S)
      • FIGURE 29     REGIONAL AND COUNTRYWISE SPECT PROCEDURAL VOLUME: (2019)(NO’S)
      • FIGURE 30     REGIONAL AND COUNTRYWISE PET PROCEDURAL VOLUME: (2019)(NO’S)
      • FIGURE 31     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 32     CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 33     CONTRAST AGENTS GLOBAL MARKET SHARE, BY MOLECULE (2019 V/S 2026) (%)
      • FIGURE 34     IODINATED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 35     IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY (2019 V/S 2026) ($MN)
      • FIGURE 36     IODINATED IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 37     MONOMER IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 38     IODINATED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 39     NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY CHEMICAL STRUCTURE (2019 V/S 2026) (%)
      • FIGURE 40     MONOMER NON-IONIC CONTRAST AGENTS MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 41     GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY CHEMICAL STRUCTURE (2019 V/S 2026) (%)
      • FIGURE 42     GADOLINIUM BASED CONTRAST AGENTS MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 43     MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 44     MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY IONICITY (2019 V/S 2026) (%)
      • FIGURE 45     NON-IONIC MACROCYCLIC CONTRAST AGENTS MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 46     MICROBUBBLE BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 47     OTHER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 48     NUCLEAR MEDICINE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 49     NUCLEAR IMAGING AGENTS GLOBAL MARKET SHARE, BY ISOTOPE (2019 V/S 2026) (%)
      • FIGURE 50     TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 51     THALLIUM (TL-201) ISOTOPE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 52     GALLIUM (GA-67) ISOTOPE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 53     IODINE (I-123) ISOTOPE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 54     XENON (XE-133) ISOTOPE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 55     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 56     GALLIUM (GA-68) ISOTOPE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 57     RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 58     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BY MODALITY (2019 V/S 2026) (%)
      • FIGURE 59     X-RAY/CT GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 60     ULTRASOUND GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 61     SPECT GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 62     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BY APPLICATION (2019) (%)
      • FIGURE 63     CARDIOVASCULAR GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 64     CANCER GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 65     GASTROINTESTINAL GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 66     MUSCULOSKELETAL GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 67     NEPHROLOGY GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 68     OBSTETRICS AND GYNECOLOGY GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 69     HEPATOLOGY GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 70     OTHERS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 71     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) (%)
      • FIGURE 72     INTRAVASCULAR GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 73     ORAL GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 74     RECTAL ADMINISTRATION GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 75     OTHERS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 76     NUCLEAR MEDICINE APPLICATION, SPECT & PET ISOTOPES
      • FIGURE 77     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BY IMAGING (2019 V/S 2026) (%)
      • FIGURE 78     DIAGNOSTIC IMAGING GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 79     MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 80     HOSPITAL GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 81     DIAGNOSTIC & AMBULATORY CENTERS GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
      • FIGURE 82     MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
      • FIGURE 83     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BY MOLECULE/ISOTOPE (2019 V/S 2026) (%)
      • FIGURE 84     NORTH-AMERICA CONTRAST AGENTS BY MOLECULE/ISOTOPE AND IODINATED AGENTS MARKET REVENUE, BY IONICITY (2019) ($MN)
      • FIGURE 85     NORTH-AMERICA NON-IONIC CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE (2019 V/S 2026) (%)
      • FIGURE 86     NORTH-AMERICA GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE (2019 V/S 2026) ($MN)
      • FIGURE 87     NORTH-AMERICA MACROCYCLIC AGENTS MARKET REVENUE, BY IONICITY (2019 V/S 2026) ($MN)
      • FIGURE 88     NORTH-AMERICA NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 89     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BY MODALITY (2019 V/S 2026) (%)
      • FIGURE 90     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BY APPLICATION (2019) (%)
      • FIGURE 91     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) (%)
      • FIGURE 92     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BY IMAGING (2019 V/S 2026) (%)
      • FIGURE 93     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 94     NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BY COUNTRY (2019 V/S 2026) ($MN)
      • FIGURE 95     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPES (2019 V/S 2026) ($MN)
      • FIGURE 96     U.S. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 97     U.S. NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 98     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 99     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 100     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 101     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 102     U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 103     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPES (2019 V/S 2026) ($MN)
      • FIGURE 104     REST OF N.A. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 105     REST OF N.A. NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 106     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 107     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 108     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 109     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 110     REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 111     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BY MOLECULE/ISOTOPE (2019 V/S 2026) (%)
      • FIGURE 112     EUROPE CONTRAST AGENTS, BY MOLECULE AND IODINATED AGENTS MARKET REVENUE, BY IONICITY (2019) ($MN)
      • FIGURE 113     EUROPE NON-IONIC CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE (2019 V/S 2026) (%)
      • FIGURE 114     EUROPE GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, CHEMICAL STRUCTURE (2019 V/S 2026) ($MN)
      • FIGURE 115     EUROPE MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY (2019 V/S 2026) ($MN)
      • FIGURE 116     EUROPE LINEAR AGENTS MARKET REVENUE, BY IONICITY (2019 V/S 2026) ($MN)
      • FIGURE 117     EUROPE NUCLEAR MEDICINE MARKET SHARE, BY ISOTOPE (2019 V/S 2026) (%)
      • FIGURE 118     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BY MODALITY (2019 V/S 2026) (%)
      • FIGURE 119     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BY APPLICATION (2019) (%)
      • FIGURE 120     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) (%)
      • FIGURE 121     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BY IMAGING (2019 V/S 2026) (%)
      • FIGURE 122     EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 123     EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BY COUNTRY (2019 V/S 2026) ($MN)
      • FIGURE 124     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 125     GERMANY CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 126     GERMANY NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 127     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 128     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 129     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 130     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 131     GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 132     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 133     FRANCE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 134     FRANCE NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 135     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 136     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 137     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 138     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 139     FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 140     U.K. MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 141     U.K. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 142     U.K. NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 143     U.K. MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 144     U.K. MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 145     U.K. MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 146     U.K. MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 147     U.K. MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 148     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPES (2019 V/S 2026) ($MN)
      • FIGURE 149     REST OF E.U. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 150     REST OF E.U. NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 151     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 152     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 153     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 154     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 155     REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 156     APAC MEDICAL IMAGING AGENTS MARKET SHARE, MOLECULE/ISOTOPE (2019 V/S 2026) (%)
      • FIGURE 157     APAC CONTRAST AGENTS, BY MOLECULE/ISOTOPE AND IODINATED MARKET REVENUE, BY IONICITY (2019) ($MN)
      • FIGURE 158     APAC NON-IONIC CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE (2019 V/S 2026) (%)
      • FIGURE 159     APAC GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE (2019 V/S 2026) ($MN)
      • FIGURE 160     APAC MACROCYCLIC CONSTRAST AGENTS MARKET REVENUE, BY IONICITY (2019 V/S 2026) ($MN)
      • FIGURE 161     APAC LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY (2019 V/S 2026) ($MN)
      • FIGURE 162     APAC NUCLEAR MEDICINE MARKET SHARE, BY ISOTOPE (2019 V/S 2026) (%)
      • FIGURE 163     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BY MODALITY (2019 V/S 2026) (%)
      • FIGURE 164     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BY APPLICATION (2019) (%)
      • FIGURE 165     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) (%)
      • FIGURE 166     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BY IMAGING (2019 V/S 2026) (%)
      • FIGURE 167     APAC MEDICAL IMAGING AGENTS MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 168     APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY COUNTRY (2019 V/S 2026) ($MN)
      • FIGURE 169     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 170     CHINA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 171     CHINA NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 172     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 173     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 174     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 175     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 176     CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 177     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 178     JAPAN CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 179     JAPAN NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 180     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 181     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 182     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 183     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 184     JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 185     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 186     SOUTH KOREA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 187     SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 188     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 189     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 190     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 191     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 192     SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 193     REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 194     REST OF APAC CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 195     REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 196     REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 197     REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 198     REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 199     REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 200     REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 201     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BY MOLECULE/ISOTOPE (2019 V/S 2026) (%)
      • FIGURE 202     ROW CONTRAST AGENTS BY MOLECULE AND IODINATED AGENTS MARKET REVENUE, BY IONICITY (2019) ($MN)
      • FIGURE 203     ROW NON-IONIC CONTAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE (2019 V/S 2026) (%)
      • FIGURE 204     ROW GADOLINUM BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE (2019 V/S 2026) ($MN)
      • FIGURE 205     ROW MACROCYCLIC AGENTS MARKET REVENUE, BY IONICITY (2019 V/S 2026) ($MN)
      • FIGURE 206     ROW LINEAR AGENTS MARKET REVENUE, BY IONICITY (2019 V/S 2026) ($MN)
      • FIGURE 207     ROW NUCLEAR MEDICINE MARKET SHARE, BY ISOTOPE (2019 V/S 2026) (%)
      • FIGURE 208     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BY MODALITY (2019 V/S 2026) (%)
      • FIGURE 209     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
      • FIGURE 210     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) (%)
      • FIGURE 211     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BY IMAGING (2019 V/S 2026) (%)
      • FIGURE 212     ROW MEDICAL IMAGING AGENTS MARKET SHARE, BY END-USER (2019 V/S 2026) (%)
      • FIGURE 213     ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BY COUNTRY (2019 V/S 2026) ($MN)
      • FIGURE 214     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 215     TURKEY CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 216     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 217     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 218     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 219     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 220     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 221     TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 222     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 223     BRAZIL CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 224     BRAZIL NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 225     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 226     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 227     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 228     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 229     BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 230     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BY MOLECULE/ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 231     OTHERS IODINATED CONTRAST AGENTS MARKET REVENUE, BY MOLECULE (2019 V/S 2026) ($MN)
      • FIGURE 232     OTHERS NUCLEAR MEDICINE MARKET REVENUE, BY ISOTOPE (2019 V/S 2026) ($MN)
      • FIGURE 233     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BY MODALITY (2019 V/S 2026) ($MN)
      • FIGURE 234     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BY APPLICATION (2019) ($MN)
      • FIGURE 235     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2019 V/S 2026) ($MN)
      • FIGURE 236     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BY IMAGING (2019 V/S 2026) ($MN)
      • FIGURE 237     OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BY END-USER (2019 V/S 2026) ($MN)
      • FIGURE 238     KEY GROWTH STRATEGIES (2016 – 2018)
      • FIGURE 239     SWOT: BAYER GROUP
      • FIGURE 240     SWOT: BRACCO GROUP
      • FIGURE 241     SWOT: CARDINAL HEALTH, INC.
      • FIGURE 242     SWOT: CURIUM PHARMA
      • FIGURE 243     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 244     SWOT: FUJIPHARMA CO LTD
      • FIGURE 245     SWOT: GE HEALTHCARE
      • FIGURE 246     SWOT: GUERBET
      • FIGURE 247     SWOT: JUBILANT LIFESCIENCE
      • FIGURE 248     SWOT: LANTHEUS MEDICAL IMAGING INC.
      • FIGURE 249     SWOT: NOVARTIS (AAA)

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     AVID RADIOPHARMACEUTICALS, INC (ELI LILLY AND COMPANY)
      • 2     ADVANCED ACCELERATOR APPLICATIONS SA (NOVARTIS CO.)
      • 3     ARRONAX-NANTES
      • 4     AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION
      • 5     BAYER GROUP
      • 6     BEIJING BEILU PHARMACEUTICALS COMPANY LIMITED
      • 7     BIEM PHARMACEUTICALS
      • 8     BRACCO IMAGING S.P.A.
      • 9     BV CYCLOTRON
      • 10     CANADIAN ISOTOPE INNOVATIONS CORP.
      • 11     CARDINAL HEALTH
      • 12     CENTER OF MOLECULAR RESEARCH
      • 13     CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
      • 14     CHINA NATIONAL NUCLEAR CORPORATION (CHINA ISOTOPE & RADIATION CORPORATION)
      • 15     CURIUM PHARMA
      • 16     DAIHAN PHARMA CO LTD
      • 17     DONGKOOK LIFESCIENCE
      • 18     ECKERT & ZIEGLER STRAHLEN
      • 19     ECZACIBASI-MONROL NUCLEAR PRODUCTS
      • 20     FLUORO PHARMA
      • 21     FUJIFILM CORPORATION
      • 22     FUJIPHARMA CO LTD
      • 23     FUTURECHEM CO. LTD
      • 24     GALENICA SENESE S.R.L
      • 25     GE HEALTHCARE
      • 26     GRATON PHARMA
      • 27     GUERBET
      • 28     HANA PHARM CO., LTD
      • 29     HARMONY LIFE SCIENCES
      • 30     HUAYI TECHNOLOGY CO., LTD (HUAYI ISOTOPES CO)
      • 31     IMAX DIAGNOSTIC IMAGING LIMITED
      • 32     INSTITUTE OF ISOTOPES
      • 33     INTERNATIONAL ISOTOPES INC.
      • 34     ISO-ANALYTICAL LTD.
      • 35     ISORAD LTD
      • 36     ISO-TEX DIAGNOSTICS INC.
      • 37     ISOTOPIA MOLECULAR IMAGING LTD.
      • 38     I-THEMBA LABS
      • 39     JB CHEMICALS AND PHARMACEUTICALS LTD
      • 40     JODAS EXPOIM PVT. LTD
      • 41     JSC ISOTOPE
      • 42     JUBILANT LIFESCIENCE
      • 43     LANTHEUS MEDICAL IMAGING
      • 44     MAGNUS HEALTH
      • 45     MEDICAL ISOTOPES
      • 46     NANO THERAPEUTICS
      • 47     NATIONAL INSTITUTE FOR RADIOELEMENTS (IRE)
      • 48     NIHON MEDI PHYSICS CO LTD
      • 49     NUCLEAR RESEARCH AND CONSULTANCY GROUP (NRG)
      • 50     OTSUKA PHARMACEUTICAL CO., LTD
      • 51     PARS ISOTOPE
      • 52     PERMA-FIX MEDICAL S.A.
      • 53     PHARMALUCENCE INC.
      • 54     REGE IMAGING & CINEFILMS PRIVATE LIMITED
      • 55     ROTOP PHARMAKA GMBH
      • 56     SAMYOUNG UNITECH
      • 57     SANOCHEMIA
      • 58     SHINE MEDICAL TECHNOLOGIES, INC
      • 59     SOLCOM LIMITED
      • 60     SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NTP RADIOISOTOPES SOC LTD)
      • 61     STRYKER(NOVADAQ TECHNOLOGIES)
      • 62     SWAN ISOTOPEN AG
      • 63     TAEJOON PHARM CO. LTD.,
      • 64     TRIVITRON HEALTHCARE
      • 65     UNIJULES LIFE SCIENCES LTD
      • 66     UNIMARK REMEDIES
      • 67     ZAG ZYKLOTRON AG
      • 68     ZHEJIANG STARRY PHARMA